



THE CHILDREN'S ENVIRONMENTAL
HEALTH & DISEASE PREVENTION
RESEARCH CENTER AT DARTMOUTH

Readily measurable epigenetic marks and significance

Carmen J. Marsit, PhD
Geisel School of Medicine at Dartmouth

Modes of Epigenetic Regulation

- DNA Methylation
 - Histone post-translational modification
 - Genomic Imprinting
 - RNA-mediated regulation
- Transcription Control
- Post-transcription Control
-
- The diagram illustrates the modes of epigenetic regulation. It features a list of four items on the left, each preceded by a yellow square icon. The first three items—DNA Methylation, Histone post-translational modification, and Genomic Imprinting—are grouped by a large right-facing curly bracket on the right side of the slide. This bracket is labeled 'Transcription Control'. The fourth item, RNA-mediated regulation, is positioned below the first three and is connected to the label 'Post-transcription Control' by a horizontal line.

Role for Epigenetic Mechanisms in “Normal” Tissue


- ▣ **Controls Gene Expression Potential**

Role for Epigenetic Mechanisms in “Normal” Tissue

□ Controls Gene Expression Potential

□ Cellular Response to Signals

- Growth signals
- Stressors
- Damage Signals
- By Altering Conformation & Packaging
- Highly Dynamic – ATP dependent process




Role for Epigenetic Mechanisms in “Normal” Tissue

▣ Controls Gene Expression Potential

- ▣ Cellular Response to Signals
- ▣ Differentiation and Cellular Fate


Possess the same genome, yet express different genes




Role for Epigenetic Mechanisms in “Normal” Tissue

- Controls Gene Expression Potential
 - Cellular Response to Signals
 - **Responsible for Differentiation and Cellular Fate**


Possess the same genome, yet express different genes




Epigenetic Patterning Set in Development




Epigenetic Patterning Set in Development



Epigenetic Mechanisms Differ by Tissue/Cell and Impart Distinct Functions



Epigenetic Mechanisms Differ by Tissue/Cell and Impart Distinct Functions



So...is all hope lost in examining
epigenetic variation in risk?

So...is all hope lost in examining epigenetic variation in risk?

Must consider implications of epigenetic variation to the function of the cell/tissue of measurement


Accessible Tissues for Epigenetic Risk Markers

- Peripheral Blood
 - Implications in immune function/inflammation
 - Keep in mind immune system can have systemic impacts
- Buccal Cells/Saliva
 - Potential Route of exposure – biomarkers of exposure
 - Oral epithelia/immune function
 - Ectodermal derivation – early embryonic effects that may be similar to central nervous system
- Pathologic Specimens
 - Can be useful in context of case-only studies
 - Establish etiologic contributors based on molecular subcharacterization of disease
 - Not only cancer but other surgical procedures (biopsies, reduction surgeries, gastric bypass, etc)
- Cord Blood
 - Immune Function
 - Hematopoietic stem cells
- Placenta
 - Functional organ during development
 - Transport, metabolic, endocrine, immunologic functions
- Fetal membranes/Residual tissues
 - Amnion/Chorion – markers of developmental exposures/risk & functional effects
 - Umbilical cord artery or vein – similarities to cardiovascular tissues?
- Other accessible biofluids
 - Breast Milk
 - Urine
 - Ejaculate

The Cellular Heterogeneity Problem

- Tissues are made up of a variety of types of cells
- Epigenetic mechanisms define cellular specificity
- Even with a specific cell type there may be clonal variation
 - May play important functional implications
 - Can also represent additional differentiation events
 - E.g. NK cell activation
 - Even specific isolation (FACS, microdissection may not be enough)
- In general, we sample tissues not individual cells
 - We are measuring aggregate markers across a population of cells within a sample
- Blood is the poster child
 - All tissue samples are affected in greater or lesser ways

Handling the challenge of heterogeneity



Houseman *et al.* *BMC Bioinformatics* 2012, **13**:86
<http://www.biomedcentral.com/1471-2105/13/86>





RESEARCH ARTICLE

Open Access

DNA methylation arrays as surrogate measures of cell mixture distribution

Not only controls confounding but also **UNDERSTAND EFFECT**

- When reference is known...can use methylation array data to estimate cell proportions
- Accomando Genome Biol 2014:



Methylation Array-based Estimate%

Arsenic Example

Koestler EHP 2013 (NH, urinary arsenic):

	Lymphocytes			
	CD8 ⁺ T	CD4 ⁺ T	NK cells	B cells
iAs (per µg/L)	1.18 (0.12, 2.23)*	-1.24 (-3.15, 0.68)	-0.11 (-1.83, 1.62)	-0.78 (-1.91, 0.36)
MMA ^V (per µg/L)	0.93 (-0.30, 2.15)	-0.24 (-2.62, 2.14)	-0.48 (-2.59, 1.62)	-0.68 (-1.88, 0.52)
DMA ^V (per µg/L)	0.42 (-0.80, 1.64)	-0.10 (-2.40, 2.20)	-0.37 (-2.14, 1.41)	-0.22 (-1.46, 1.01)
iAs/(iAs + MMA ^V + DMA ^V)	9.11 (0.44, 17.79)*	-11.82 (-27.66, 4.02)	-2.16 (-14.58, 10.27)	-6.05 (-16.4, 4.27)


Kile Epigenetics 2014 (Bangladesh, Water As):

	Effect Estimate (Raw) ^a [% composition]	Effect Estimate (Bias-Adj) ^b [% composition]	SE ^c	P value ^d
B cell	-1.4	-1.4	0.71	0.056
Granulocyte	1.4	1.6	1.84	0.430
Monocyte	0.5	0.5	0.50	0.310
Natural Killer	-0.7	-0.9	0.73	0.317
T Cell (CD4+)	-7.4	-9.2	1.97	0.0002
T Cell (CD8+)	5.5	7.4	1.54	0.0004

Why cell composition is important

- Likely reflects the “effect” of the variation in epigenetic mark
- Example – GPR15 hypomethylation associated with smoking

Bauer et al. *Clinical Epigenetics* (2015) 7:81
DOI 10.1186/s13148-015-0113-1



CLINICAL
EPIGENETICS

RESEARCH

Open Access

A varying T cell subtype explains apparent tobacco smoking induced single CpG hypomethylation in whole blood



Challenges and Opportunities for Epigenetic Biomarkers

- Major questions remain about interpretation
 - Cell composition effect
 - Must be placed in context of tissue studied
 - Unlikely to be a reliable **surrogate** marker
- Consideration/Incorporation of various types of epigenetic mechanisms
 - DNA Methylation
 - Genomic Imprinting
 - Chromatin Modification
 - Small non-coding RNA (miRNA, rRNA, etc)
 - Long non-coding RNA (lncRNA)
 - Alternative splicing
- Other marks suffer from same challenges as well as more
 - Technological challenges – might be overcome with novel methods
- Potentially useful risk, clinical, interventional biomarkers

Acknowledgments

▣ Colleagues

- ▣ Karl Kelsey – Brown
- ▣ E. Andres Houseman – Oregon State
- ▣ Devin Koestler – U. Kansas
- ▣ John Wiencke - UCSF
- ▣ Heather Nelson – U. Minnesota
- ▣ Margaret Karagas - Dartmouth
- ▣ Brock Christensen – Dartmouth
- ▣ Jia Chen – Mt. Sinai School of Medicine

▣ Funding

- ▣ NIMH
 - ▣ R01MH094609
- ▣ NIEHS
 - ▣ R01ES022223
 - ▣ P01 ES022832
- ▣ US EPA
 - ▣ RD83544201



THE CHILDREN'S ENVIRONMENTAL
HEALTH & DISEASE PREVENTION
RESEARCH CENTER AT DARTMOUTH